GlassScriptPhysician profile
Stephen T Foley
NPI 1497701841
$909.88
in general payments reported to CMS, 2019-2025
28 companies · $96.60 in 2025
The $96.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $37.02 · 2021: $158 · 2022: $179 · 2023: $150 · 2024: $131 · 2025: $96.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $124.86 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $86.37 | 2019-2023 | |
| Amgen INC. | $74.98 | 2019-2025 | Evenity, Repatha, Otezla |
| Allergan, INC. | $65.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.31 | 2020-2021 | |
| Glaxosmithkline, LLC. | $42.60 | 2022-2023 | Arexvy |
| Teva Pharmaceuticals USA, INC. | $40.25 | 2019-2022 | |
| Alkermes, INC. | $38.08 | 2021-2022 | |
| Abbvie INC. | $36.70 | 2023 | |
| Lilly USA, LLC | $36.54 | 2021-2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $29.46 | 2021-2024 | Eliquis |
| Sunovion Pharmaceuticals INC. | $28.26 | 2019 | |
| Boston Scientific Corporation | $22.50 | 2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.49 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.79 | 2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.16 | 2023 | Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $17.35 | 2021 | |
| Inspire Medical Systems, INC. | $17.35 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $14.81 | 2022 | |
| Almatica Pharma LLC | $14.53 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.21 | 2025 | Uptravi, Opsumit |
| Dexcom, INC. | $14.17 | 2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $14.13 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.01 | 2025 | |
| Novo Nordisk INC | $13.26 | 2024 | |
| Sanofi-Aventis U.S. LLC | $12.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.11 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.